Clinical Trials Sponsored by Concert Pharmaceuticals

Total 50848 results

Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Concert Pharmaceuticals

Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Health Volunteers

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

Healthy

Australia
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-656 in Healthy Male Volunteers

Healthy

Australia
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

Healthy

Australia
Concert Pharmaceuticals

Completed

A Safety and Tolerability Study of CTP-730 in Healthy Volunteers

Healthy

Australia
Concert Pharmaceuticals

Completed

A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Narcolepsy, Excessive Daytime Sleepiness

United Kingdom
Concert Pharmaceuticals

Completed

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

Healthy Volunteers
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Active, not recruiting

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

Spain, Germany, Poland, France, Hungary
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Health Volunteers

United States
Concert Pharmaceuticals

Completed

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

Health Volunteers

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States
Concert Pharmaceuticals

Completed

Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656

Healthy

Australia
Concert Pharmaceuticals

Completed

Multiple Ascending Dose Study in Healthy Volunteers

Healthy

Australia
Concert Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Diabetic Nephropathy

United States
Concert Pharmaceuticals

Completed

A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Alopecia Areata

Spain, United States, Poland, Canada, France, Germany, Hungary
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)

Alopecia Areata

United States, Canada, Poland, France, Spain
Concert Pharmaceuticals

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
Concert Pharmaceuticals

Completed

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

Healthy Volunteers

Australia
Concert Pharmaceuticals

Completed

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

Stage 3 Chronic Kidney Disease

United States
Concert Pharmaceuticals
Celerion

Completed

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Healthy Volunteers

United States
Concert Pharmaceuticals
Celerion

Completed

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Healthy Volunteers

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States

3

Subscribe